Estonian Microarray Startup Hopes to Capture SNP Market | GenomeWeb

NEW YORK, March 2 - Tartu, Estonia may seem an unlikely launch point for a global assault on the SNP chip market. But Asper Biotech, a small Estonian microarray startup, hopes to leverage its unique chip-based sequencing technology to do just that. 

"Asper's edge is that manufacturing on a chip and reagent costs are way lower," than other SNP sequencing methods, said Kalev Kask, director of Asper's US office. "Our cost is definitely below 50 cents a SNP right now."  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.